Review of Japanese Encephalitis Vaccines in India

Japanese encephalitis virus belongs to the genus Flavivirus. Case fatality averages 30% and almost 50% of the survivors are left with permanent neuropsychiatric sequelae. Japanese encephalitis occurs in nearly all Asian countries including India. Patterns of JE transmission vary within individual co...

Full description

Saved in:
Bibliographic Details
Published in:Asian Pacific Journal of Health Sciences 2022-06, Vol.9 (4), p.272-283
Main Authors: Chatterjee, Kripasindhu, Bhadra, Atanu, Ray, Swapan Kumar, Mukherjee, Subhasis, Sen, Sukanta
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Japanese encephalitis virus belongs to the genus Flavivirus. Case fatality averages 30% and almost 50% of the survivors are left with permanent neuropsychiatric sequelae. Japanese encephalitis occurs in nearly all Asian countries including India. Patterns of JE transmission vary within individual countries and from year to year. In endemic areas, sporadic cases occur throughout the year. Japanese encephalitis or AES has been reported from 231 districts of 23 states. The best way to control JE in humans is through vaccination. Currently available vaccines in India are live attenuated, cell culture-derived SA 14-14-2, inactivated SA 14-14-2 vaccine (IC51; IXIARO® by Intercell and JEEV® by Biological Evans India Ltd.) and inactivated Vero cell culture-derived Kolar strain, 821564XY, JE vaccine (JENVAC® by Bharat Biotech). As 2006 position paper of WHO stated that mouse brain derived vaccines should be withdrawn and replaced by newer vaccines due to safety profile and as it is not available in our country now, this vaccine will not be discussed henceforth.
ISSN:2350-0964
2349-0659
DOI:10.21276/apjhs.2022.9.4.53